•A Randomized, Placebo-Controlled, Double-Blind, Parallel Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of LTI-291 in Patients with Parkinson’s Disease and a GBA1 Mutation

•Lysosomal Therapeutics, Incorporated0 sites40 target enrollmentTBD

ConditionsPD patients with a GBA1 mutation , movement disorder

Overview

Phase: N/A
Intervention: Not specified
Conditions: PD patients with a GBA1 mutation , movement disorder
Sponsor: •Lysosomal Therapeutics, Incorporated
Enrollment: 40
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

•Lysosomal Therapeutics, Incorporated

Eligibility Criteria

Inclusion Criteria

•1\.Signed informed consent prior to any study\-mandated procedure.
•2\.Minimum age of 18 years.

Exclusion Criteria

•1\.Any active or chronic disease or condition other than PD that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following medical history review, physical examination, vital signs (supine systolic and diastolic blood pressure, pulse rate, body temperature), 12\-lead electrocardiogram (ECG), and clinical laboratory parameters (hematology, blood chemistry, and urinalysis)). Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance.
•2\.History of recent major surgery (within 60 days of screening) that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

N/A

Multicenter clinical study of the efficacy and safety of the Ongyeong-tang(OKT) for Coldness of Feet(Cold Hypersensitivity in Feet)Not Applicable

KCT0003723Sangji University Oriental Medical Center112

Active, Not Recruiting

Phase 2

Test of the effect of 1-Kestose on the intestinal environment of Pregnant Women.

JPRN-jRCTs031210087Ide Yoshihiro70

Completed

N/A

A Randomized, Placebo-Controlled, Double-Blind, Parallel Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of LTI-291 in Patients with Parkinson*s Disease and a GBA1 MutatioGBA-Associated Parkinson's Diseasemovement disorder10028037

NL-OMON44216ysosomal Therapeutics Incorperated40

Active, Not Recruiting

Phase 1

Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prevention of Episodic Cluster Headache

EUCTR2012-003729-62-GBCENTER LABORATORIES, INC30

Active, Not Recruiting

Phase 1

Prevention of cardiovascular events (eg, death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin.

EUCTR2009-017242-30-ROAstraZeneca AB21,162